Achieve The Scoop Around DMXAA Before You Are Too Late

Hepatitis B is an important disease worldwide and over one-third [ask author to provide http://www.selleckchem.com/products/Aloxistatin.html a reference. According to WHO, 350?million people are chronically infected with HBV, i.e. about 6% (not 30%) of the world population] of the world population is infected with the hepatitis B virus (HBV). Distribution of the disease is not homogenous; it is more prevalent in certain parts of South East Asia and Africa [1]. HBV infection is a heterogeneous disease. HBeAg-positive patients account for 10% to 35% of chronic hepatitis B cases in Europe [2]. In general, HBeAg-positive patients are in the earlier phases of the disease, the immune-tolerant or immune-clearance phases, which are characterized by high levels of HBV DNA. Chronic HBV infection (CHB) is a cause of considerable morbidity and mortality, both of which are linked to ongoing HBV replication. There is convincing evidence that persistent active viral replication is an independent predictor of disease progression. Indeed, a large prospective cohort study has demonstrated that elevated HBV DNA levels (>104?copies/ml) significantly increase the risk of cirrhosis, hepatocellular carcinoma (HCC) and death over a 10-year period [3, 4]. Therefore, sustained suppression of HBV replication is the cornerstone for preventing disease progression and prolonging survival in CHB patients. In addition, treatment of existing carrier forms is important for controlling the disease by reducing HBV infectivity. In HBeAg-positive patients, international guidelines on http://en.wikipedia.org/wiki/Resveratrol the management of CHB suggest that either pegylated interferon (PEG-IFN) or nucleos(t)ide analogues (NAs) such as entecavir (ETV) or tenofovir disoproxil fumarate (TDF) can be used as first-line therapy, although there are no specific recommendations on how to choose between these two treatments [1, 5, 6]. Therefore, the choice of PEG-IFN or a NA is the personal decision of the treating physician. In this review, the arguments supporting the use of NAs as first-line therapy in HBeAg-positive patients are addressed. Nucleos(t)ide analogues are currently the most potent drugs for suppressing hepatitis B virus replication, and this action is associated with http://www.selleckchem.com/products/DMXAA(ASA404).html better disease outcome. The ultimate aim of CHB treatment is to prevent or decrease the development of HCC and cirrhosis, and these endpoints are reached by the suppression of viral replication. Registration studies in HBeAg-positive patients have shown that ETV and TDF are the most potent drugs for suppressing viral replication and are better than PEG-IFN. Serum HBV DNA levels were reduced to